Author Archive for Insider Scoop

Mid-Morning Market Update: Markets Mostly Flat; G-III Apparel Misses Q2 Expectations

Courtesy of Benzinga.

Following the market opening Tuesday, the Dow traded down 0.07 percent to 18,489.98 while the NASDAQ gained 0.06 percent to 5,235.35. The S&P also fell, dropping 0.03 percent to 2,179.81.

Leading and Lagging Sectors

Tuesday morning, energy shares gained by 0.58 percent. Meanwhile, top gainers in the sector included Approach Resources Inc. (NASDAQ: AREX), and Comstock Resources Inc (NYSE: CRK).

In trading on Tuesday, basic materials shares fell by 0.51 percent. Meanwhile, top losers in the sector included DRDGOLD Ltd. (ADR) (NYSE: DRD), down 4 percent, and Randgold Resources Ltd. (ADR) (NASDAQ: GOLD), down 2 percent.

Top Headline

G-III Apparel Group, Ltd. (NASDAQ: GIII) reported weaker-than-expected results for its second quarter and lowered its full-year guidance.

The company suffered a net loss of $1.3 million or a loss per share of $0.03 compared to net income of $12.5 million or $0.27 a share in the year-ago period. Results included professional fees of about $0.04 a share. Excluding this, it would have earned $0.01 a share, which is sharply lower than the Street estimates of $0.18 a share.

G-III Apparel’s net sales witnessed 7 percent drop from $473.9 million to $442.3 million and missed the analysts’ predictions of $484.85 million.

Equities Trading UP

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares shot up 34 percent to $3.54 as the company disclosed that fostamatinib, its oral spleen tyrosine kinase inhibitor, met the primary endpoint in the final stage trial program for adult chronic/persistent immune thrombocytopenia treatment.

Shares of Karyopharm Therapeutics Inc (NASDAQ: KPTI) got a boost, shooting up 18 percent to $8.38. Jefferies…
continue reading

BHP Billiton Raised To Buy At Argus On Positive Outlook For Materials

Courtesy of Benzinga.

BHP Billiton Raised To Buy At Argus On Positive Outlook For Materials

Although sales and earnings at BHP Billiton Limited (ADR) (NYSE: BHP) have been hit by declining commodity prices, many product prices seem to be “nearing a cycle bottom,” Argus’s John Eade said in a report. He upgraded the rating on the company to Buy, while establishing a price target of $40.

Management’s FY17 FCF guidance of $7 billion assumes productivity gains and stable commodity prices.

Benefits To Earnings

Analyst Eade commented that BHP Billiton’s are poised to benefit from “stable-to-higher commodity prices,” with prices for many products nearing a cycle bottom. Argus analysts recently raised their rating on the Materials sector to Overweight.

Related Link: Investors Can Buy Shares Of BHP Billiton Plc Or BHP Billiton Ltd.: What Is The Difference?

BHP Billiton has been able to offset the adverse impact of weak pricing and strengthen its balance sheet through cost control initiatives, asset sales, and a substantial cut in its semiannual dividend. The company’s earnings are expected to continue to benefit from management’s actions to lower costs, Eade added.

Moreover, earnings may be boosted over time by “global economic stimulus measures” as well as production cuts in China.

Although BHP Billiton’s shares have outperformed the S&P 500 over the past quarter, they are trading substantially below their 10-year high above $100, the analyst commented.

Do you have ideas for articles/interviews you’d like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for BHP

Date Firm Action From To
Aug 2016 Argus Research Upgrades Hold Buy
Aug 2016 Jefferies Upgrades Hold Buy
Apr 2016 Bank of America Upgrades Neutral Buy

View More Analyst Ratings for BHP

View the Latest Analyst Ratings

Posted-In: ArgusAnalyst Color Long Ideas Upgrades Commodities Markets Analyst Ratings Trading Ideas Best of Benzinga

Orexigen Shares Up 14% After Commercialization, Distribution Deal With Valeant Canada

Courtesy of Benzinga.

Orexigen Shares Up 14% After Commercialization, Distribution Deal With Valeant Canada

Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Valeant Canada, a subsidiary of Valeant Pharmaceuticals Intl Inc (NYSE: VRX), struck an agreement on commercialization and distributorship for Contrave. Following the news, Orexigen traded up by more than 12 percent in the pre-market trading.

Orexigen said that the agreement terms made Valeant responsible for receiving regulatory approval from Canada for all commercialization activity and expenses. The company would supply Contrave tablets for an agreed transfer price based on some potential regulatory and sales milestone payments.

The American firm expects the Canadian firm to file for regulatory approval with Health Canada before January next year. Both the companies disclosed a commercialization deal for Mysimba earlier in March, and they expect to launch the product in 11 nations in the fourth quarter of the current year.

Related Link: Orexigen Reports Commercialization, Distributorship Deal with Laboratorios Farmaceuticos Rovi in Spain

Orexigen CEO Mike Narachi said, “Valeant Canada has a growing portfolio of innovative medicines addressing cardiometabolic disease, as well as strong regulatory and commercial capabilities, and we believe they are an ideal partner for Contrave in Canada. Partnering with strong pharmaceutical companies outside the United States supports our global mission to improve the health and lives of patients struggling to lose weight and allows Orexigen to realize the global value of Contrave / Mysimba.”

While Orexigen traded up by 14.85 percent to $4.40, Valeant traded down by 1.62 percent, to $29.75 at time of publication minutes after Tuesday’s opening bell.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you’d like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Posted-In: Contrave Health CanadaBiotech News Health Care Movers Press Releases General Best of Benzinga

Pacific Crest Downgrades Imperva, Expects Longer Than Expected Delay For Performance To Improve

Courtesy of Benzinga.

Imperva Inc’s (NYSE: IMPV) fundamentals “continue to be challenged” and an improvement in the company’s performance would likely take longer than expected by the Street, Pacific Crest’s Rob Owens said in a report. He downgraded the rating on Imperva to Sector Weight, commenting that the company’s shares could come under pressure if a sale is not consummated soon.

Shares Appear Elevated

On August 4, Imperva had announced details of its weaker-than-expected Q2 results. Despite this, shares appreciated 3.6 percent, probably on management’s comments indicating the commencement of a review of strategic alternatives, analyst Owens mentioned.

Shares now represent “a less compelling investor return profile,” and would come under pressure if the company is unable to find a suitor in the near term, since there seems to be “no chance” a meaningful improvement in fundamentals anytime soon, Owens stated.

Prolonged Turnaround

During Q2, Imperva’s performance was adversely impacted by declining deal sizes, prolonged sales cycles and difficult comps.

“While management had previously attributed its success and strong pipeline build to its depth of management and vigilance building pipeline, the majority of the team praised on the fourth quarter conference call are no longer with the company,” the analyst pointed out, adding that this created a difficult backdrop for any rebound in performance in the near term.

Do you have ideas for articles/interviews you’d like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for IMPV

Date Firm Action From To
Aug 2016 Pacific Crest Downgrades Overweight Sector Weight
Aug 2016 Wunderlich Downgrades Buy Hold
Jul 2016 Evercore ISI Group Initiates Coverage on Hold

View More Analyst Ratings for IMPV

View the Latest Analyst Ratings

Posted-In: Pacific Crest Rob OwensAnalyst Color Downgrades Analyst Ratings

A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Consumer Confidence Report

Courtesy of Benzinga.

A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Consumer Confidence Report

Pre-open movers

U.S. stock futures traded mostly lower in early pre-market trade. The S&P/Case-Shiller home price index for June will be released at 9:00 a.m. ET, while the Conference Board’s consumer confidence index for August is schedule for release at 10:00 a.m. ET.

Futures for the Dow Jones Industrial Average fell 1 point to 18,488.00, while the Standard & Poor’s 500 index futures fell 0.75 points to 2,178.75. Futures for the Nasdaq 100 index declined 8.25 points to 4,785.00.

Oil prices traded higher as Brent crude futures gained 0.53 percent to trade at $49.52 per barrel, while US WTI crude futures also rose 0.70 percent to trade at $47.31 a barrel.

A Peek Into Global Markets

European markets were higher today, with the Spanish Ibex Index rising 0.69 percent, STOXX Europe 600 Index gaining 0.44 percent and German DAX 30 index gaining 0.87 percent. The UK’s FTSE index was trading higher by 0.03 percent, while French CAC 40 Index climbed 0.76 percent.

In Asian markets, Japan’s Nikkei Stock Average fell 0.07 percent, Hong Kong’s Hang Seng Index rose 0.85 percent, China’s Shanghai Composite Index gained 0.15 percent and India’s BSE Sensex gained 1.58 percent.

Broker Recommendation

Analysts at Baird upgraded McDonald’s Corporation (NYSE: MCD) from Neutral to Outperform.

McDonald’s shares fell 0.10 percent to $115.30 in pre-market trading.

Breaking news

  • G-III Apparel Group, Ltd. (NASDAQ: GIII) reported weaker-than-expected results for its second quarter and lowered its full-year guidance.
  • Shares of Apple Inc. (NASDAQ: AAPL) fell more than 2 percent Tuesday morning after the European Union slapped the company with a whopping 13 billion euro ($14.5 billion) bill for back taxes. The EU concluded that Ireland gave Apple illegal state aid over many years. To read the full news, click here.
  • Christopher & Banks Corporation (NYSE: CBK) posted a wider-than-expected loss for the second quarter on Tuesday.
  • Kamada Ltd (NASDAQ: KMDA) disclosed favorable top-line results of its second stage trial on inhaled Alpha-1 Antitrypsin that met primary endpoint. To read the full news, click here.

Posted-In: Earnings News Guidance Eurozone Futures Global Pre-Market Outlook Markets

Technical Alert: General Electric Nears Upper-End Of 24 Day Trading Range

Courtesy of Benzinga.

  • $31.57 – August 23 high
  • $31.56 – July 27 high
  • $31.47 – Intraday highs as of 12:47 PM
  • $31.41 – Current price as of 12:47 PM
  • $31.36 – Monday close
  • $31.30 – Intraday low as of 12:47 PM

If content like this is useful to your trading/investing strategy, please email with the headline to let us know

Posted-In: Technicals Intraday Update Movers Trading Ideas

Canaccord Lifts Ambarella Price Target From $65 To $85, Expects GoPro Sales Recovery

Courtesy of Benzinga.

Although the much publicized recent struggle that Ambarella Inc (NASDAQ: AMBA) has been part of with its key customer, GoPro Inc (NASDAQ: GPRO), are likely to impact the July quarter results, Canaccord Genuity’s Matthew D. Ramsay believes that “strength in drones, home security and other markets should drive results above the guidance midpoint.”

Ramsay reiterated a Buy rating on Ambarella, while raising the price target from $65 to $85.

What Will Drive Performance?

“Further, we anticipate broadening strength in camera demand and a recovery of sales into GoPro to support the HERO5 launch will drive 2H/F’17 results solidly above consensus, though anticipated quarterly seasonality remains unclear given the image sensor supply disruption at Sony due to the earthquake earlier this year,” the analyst mentioned.

Canaccord’s research indicates there is likely to be ample supply of sensors to support the holiday volumes from large customers like GoPro.

However, some smaller vendors are likely to see volumes pushed into Ambarella’s January quarter, marginally impacting the October quarter guidance upside and the historical January quarter downward seasonality.

Guidance Revised

“Overall, we anticipate a strong 2H/F’17 for Ambarella and believe full year results will achieve updated revenue guidance for flat to down 5 percent, implying strong mid-teens topline growth during the 2H,” Ramsay stated.

Although this is lower than the initial growth target of 15-20 percent that the company had guided to at the start of the year, the analyst believes that the revised guidance reflects the strength of the diversifying business, against a backdrop of meaningful impacts from GoPro and Sony Corp (ADR) (NYSE: SNE).

Do you have ideas for articles/interviews you’d like
continue reading

19% Upside In Cabot Oil In Williams Capital’s View

Courtesy of Benzinga.

19% Upside In Cabot Oil In Williams Capital's View

While stating that the E&P sector fundamentals were solid, Williams Capital’s Gabriele Sorbara recommended to select “underappreciated companies with lower expectations and re-rating potential.” The analyst initiated coverage of Cabot Oil & Gas Corporation (NYSE: COG) with a Buy rating and a price target of $30.

Strong Production Growth

“Despite the issues witnessed over the past few years with Constitution pipeline and the bottlenecks in the Northeast Appalachia region, COG has been successful in securing additional takeaway capacity,” analyst Sorbara wrote.

Cabot Oil has about 200,000 net acres in the Marcellus shale play in Susquehanna County, Pennsylvania, which is located in a “sweet spot” and represents “superior economics,” Sorbara commented.

Related Link: Oil Heading Toward Largest Weekly Decline In A Month

The company seems to be on track to support Marcellus production of 3.5 Bcf/d gross by yearend 2018, up from the 2Q16 level of 1.8 Bcf/d gross. This would enable Cabot Oil to generate solid production growth in 2018 and beyond.

Best Play On Natural Gas Market Improvement

The analyst believes Cabot Oil’s stock deserves to trade at a premium to that of its peers, given the company’s resource upside potential in the Marcellus shale play and expectations of strong EBITDA growth. “Furthermore, we believe COG is the best way to play an improving natural gas market with its improving capital efficiencies.”

Cabot Oil’s shares have underperformed YTD, having gained 42.6 percent, versus the average gain by peers of 67.7 percent. This offers “a solid entry point to add or build a position ahead of the winter natural gas demand season,” Sorbara stated.

Do you have ideas for articles/interviews you’d like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for COG

Date Firm Action From To
Aug 2016 Williams Capital Group Initiates Coverage on Buy
Aug 2016 Drexel Hamilton Maintains Buy
Aug 2016 Scotia Howard Weil Upgrades Sector Perform Sector Outperform

View More Analyst Ratings for COG

View the Latest Analyst Ratings

Posted-In: Gabriele SorbaraAnalyst Color Long Ideas Commodities Initiation Markets Analyst Ratings Trading Ideas Best of Benzinga

5 Biggest Price Target Changes For Monday

Courtesy of Benzinga.

  • Deutsche Bank raised the price target for Micron Technology, Inc. (NASDAQ: MU) from $15 to $20. Micron shares closed at $16.51 on Friday.
  • Nomura boosted Tiffany & Co. (NYSE: TIF) price target from $64 to $76. Tiffany shares closed at $73.56 on Friday.
  • Citigroup cut the price target for Compania Cervecerias Unidas S.A. (ADR) (NYSE: CCU) from $25.50 to $24.50. Compania Cervecerias Unidas shares closed at $21.82 on Friday.
  • FBR Capital increased the price target on Metlife Inc (NYSE: MET) from $51 to $54. Metlife shares closed at $41.79 on Friday.
  • Argus raised HP Inc (NYSE: HPQ) price target from $16 to $19. HP shares closed at $14.39 on Friday.

Latest Ratings for CCU

Date Firm Action From To
Aug 2016 Citigroup Downgrades Buy Neutral
Jan 2016 Goldman Sachs Upgrades Sell Neutral
Nov 2015 Deutsche Bank Downgrades Buy Hold

View More Analyst Ratings for CCU

View the Latest Analyst Ratings

Posted-In: Price Target ChangesPrice Target Analyst Ratings

Axiom Initiates Netflix At Sell, Has Concerns Of Rising Content Costs

Courtesy of Benzinga.

Axiom Initiates Netflix At Sell, Has Concerns Of Rising Content Costs

Netflix, Inc. (NASDAQ: NFLX) could miss the consensus expectations for longer-term subscriber growth and profits due to intensifying competition, diminishing pricing power, and rising content costs. Axiom’s Victor Anthony initiated coverage of the company with a Sell rating and $80 price target.

The longer-term secular growth story for Internet TV remains intact, while Netflix would likely continue to play a leading role in “disrupting the linear-TV experience.”

The company has a collection of high-quality original content and its range of TV shows and movies should continue to appeal to consumers of video content. Anthony added, however, that Netflix’s ability to meet the longer-term subscriber growth and profit estimates may come under pressure.

Related Link: William Blair Upgrades Netflix, Sees 50% Upside: ‘Advantage In Original Content & Millennials Underappreciated’

Dealing With Competition, Increased Content Needs

Despite rising competition, Netflix has been able to double its domestic subscriber base from the 2011 levels. However, domestic subscriber growth has decelerated off late, partly due to competition.

“Netflix is now seeing heightened competition for both subscribers and content licensing primarily from Amazon, Hulu, and HBO, and several other online streaming services launched in the U.S. and internationally over the past two years, with several more to come,” the analyst wrote.

Netflix could face increased churn in the back half of 2016 due to recent price hikes. Moreover, the company faces tougher comps in 2H16 and 1H17, after having launched its services in more than 100 countries in 1Q16.

Another aspect of these launches is that those markets would demand local content, forcing Netflix to either spend more on licensing or developing original content, which would exert pressure on its international profitability goals, or spend less, and risk losing subscribers.

“Investors are paying a super-rich multiple that, in our minds, calls for near flawless execution, an expectation we believe will be hard to achieve,” Anthony commented.

Do you have ideas for articles/interviews you’d like to
continue reading


Zero Hedge

Debt, Deficits & Economic Warnings

Courtesy of ZeroHedge. View original post here.

Submitted by Lance Roberts via,

While the world has been focused on the Federal Reserve, the markets, and the upcoming election, few have noticed the expansion of the deficit in recent months which is now in excess of $667 billion up from a recent low of $530 billion. The chart below shows the history of U.S. surplus/deficit:

During the financial crisis, the deficit ballooned to a record of $1.35 trillion ...

more from Tyler

Chart School

Little Change

Courtesy of Declan.

I'm waiting for bears to step in and reverse the nascent breakout but it hasn't happened yet. The intraday range was tight and the change relative to yesterday was small. This left little to add.

The S&P still has three 'sell' triggers in MACD, On-Balance-Volume and ADX to work off before the rally resumes.

The Nasdaq is creating a mini-bear flag, although confirmation will require a single day loss of at least 1%. It has a more solid technical picture than the S&P.


more from Chart School


Michael Mauboussin - Market Myths And Market Reality

By VW Staff. Originally published at ValueWalk.

Michael Mauboussin – Market Myths And Market Reality

Michael Mauboussin is the author of The Success Equation: Untangling Skill and Luck in Business, Sports, and Investing (Harvard Business Review Press, 2012), Think Twice: Harnessing the Power of Counterintuition (Harvard Business Press, 2009) and ...

more from ValueWalk

Phil's Favorites

A Two-Bar Pattern that Points to Trade Setups


A Two-Bar Pattern that Points to Trade Setups

By Elliott Wave International

Some people like to get outside on the weekends, maybe playing tennis or working in the yard. Some people like to visit their friends or cook a big meal or go out to see a movie. And some people who are passionate about their work -- such as Elliott Wave International's futures analyst Jeffrey Kennedy -- like to stare at hundreds of price charts on their computer screen to find patterns that point to trade setups. We used to worry for his health but not anymore, because he's been doing it for years and he comes up with some neat stuff. A case in point is his discovery of a two-bar pattern that he named the Popgun. Find out more in this excerpt from the Club EWI eBoo...

more from Ilene

Market News

News You Can Use From Phil's Stock World


Financial Markets and Economy

Fed’s Fischer Says Negative Rates Seem to Work in Today’s World (Bloomberg)

Federal Reserve Vice Chairman Stanley Fischer said negative interest rates seem to be working in other countries, while reinforcing that they aren’t on the table in the U.S.

French Trade Minister Says U.S. Talks Dead as TTIP Wobbles (Bloomberg)


more from Paul

Kimble Charting Solutions

US Dollar/Yen testing important support zone

Courtesy of Chris Kimble.

The US Dollar/Yen is facing a trio of potential support lines at this time with few people bullish the US$/Yen at Stocktwits. What happens at this potential support zone, could well impact the Risk On trade from now until year end.


The trend in the US$/Yen remains down for the past few months, as the YEN has been stronger than the US$. The US$/YEN remains inside of a steep falling channel over the past 10-months.

The bottom of this steep falling channel and two ot...

more from Kimble C.S.


Swing trading portfolio -week of August 29th, 2016

Reminder: OpTrader is available to chat with Members, comments are found below each post.


This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...

more from OpTrader


Epizyme - A Waiting Game

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Epizyme was founded in 2007, and trying to create drugs to treat patient's cancer by focusing on genetically-linked differences between normal and cancer cells. Cancer areas of focus include leukemia, Non-Hodgkin's lymphoma and breast cancer.  One of the Epizme cofounders, H. Robert Horvitz, won the Nobel Prize in Medicine in 2002 for "discoveries concerning genetic regulation of organ development and programmed cell death."

Before discussing the drug targets of Epizyme, understanding epigenetics is crucial to comprehend the company's goals.  

Genetic components are the DNA sequences that are 'inherited.'  Some of these genes are stronger than others in their expression (e.g., eye color).  Yet, some genes turn on or off due to external factors (environmental), and it is und...

more from Biotech

Digital Currencies

Man Who Introduced Millions to Bitcoin Says Blockchain Is a Bust


Man Who Introduced Millions to Bitcoin Says Blockchain Is a Bust 

By  at Bloomberg


Stefan Thomas, who introduced millions of people to bitcoin, has had a change of heart.

Blockchain, the ledger software that makes the digital currency possible...

more from Bitcoin

Mapping The Market

Illusion of Choice

From Jean-Luc:

Looks like we are down to about 10 companies for our consumer goods:

Just like banks, airlines and cable companies! 

The Illusion of Choice in Consumer Brands

Explore the full-size version of the above graphic in all its glory.

If today’s infographic looks familiar, that’s because it originates from a well-circulated report that Oxfam International puts together to show consolidation i...

more from M.T.M.

All About Trends

Mid-Day Update

Reminder: Harlan is available to chat with Members, comments are found below each post.

Click here for the full report.

To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David


PSW is more than just stock talk!


We know you love coming here for our Stocks & Options education, strategy and trade ideas, and for Phil's daily commentary which you can't live without, but there's more! features the most important and most interesting news items from around the web, all day, every day!

News: If you missed it, you can probably find it in our Market News section. We sift through piles of news so you don't have to.   

If you are looking for non-mainstream, provocatively-narrated news and opinion pieces which promise to make you think -- we feature Zero Hedge, ...

more from Promotions

Help One Of Our Own PSW Members

"Hello PSW Members –

This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible.  Feel free to contact me directly at with any questions.

Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts.  After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.)  Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.

Thank you for you time!

FeedTheBull - Top Stock market and Finance Sites

About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>

As Seen On:

About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>